semaglutide staten island Weight Loss - & More Explore Peptide Therapy in Staten

Analysis A recent Cleveland Clinic study, published in Obesity Journal, indicates that popular GLP-1 weight-loss drugs, including Novo Nordisk's semaglutide (Wegovy, Ozempic) and Eli Lilly's tirzepatide (Zepbound, Mounjaro), demonstrate lower effectiveness in real-world settings compared to the outcomes observed in randomized clinical trials

Ive certainly seen lots of chatter about the dangers of muscle loss with Ozempic, and the need to pound protein and lift weights

Semaglutide, a medication approved for the treatment of these conditions, has emerged as a focal point of interest due to its broad applicability and effectiveness

Further mediation analysis indicated that this effect might be unrelated to improvements in glycemic control but rather mediated by BMI

doi: 10.3389/fphar.2025.1562896

The dominant reasons, documented across multiple 2025 real-world studies, are: cost and insurance denials (47.6% of discontinuations), intolerance of GI side effects (14.6%), and supply shortages (11.8%)